Cardiotoxicity is a major concern in chemotherapies, and hence the mechanisms underlying chemotherapy-induced cardiotoxicity attract substantial interest in healthcare systems. The drive for improving the effectiveness of chemotherapies, such as in breast cancer in recent years, has bolstered clinical trials and other similar research in the cardiotoxicity market.
Chemoterapics drugs have oftentimes been associated with cardiotoxicity, leading to myocardial dysfunction and even irreversible heart failure. Frequently, these risks have been confirmed by the parameters of echocardiography used in clinical settings. Over the years, a growing body of research and advances in imagistic methods have underscore such research. Evolution in cardio-oncology field has been charting the growth trajectories in the cardiotoxicity market.
The study offers a critical assessment of the clinical research directions that will shape notable avenues in the cardiotoxicity market. The research also takes a closer look at factors and the dynamics that influence the current and emerging competitive landscape, along with the share and revenue size of various key segments during the forecast period of 2020 – 2030.
Do you want to assess potential implications of COVID-19 pandemic on your business and boost your preparedness? Grab an exclusive sample for this report!
The strides in the cardiotoxicity market are influenced by the adoption of targeted anticancer agents. Resultantly, interested stakeholders are evaluating the cardiovascular complication (CVC) potential associated with the currently accepted chemotherapies. CVS, among other risk factors, have been bothering cancer patients who are on prolonged chemotherapies. Numerous regulatory bodies highlight the key risk factors of chemotherapy-induced cardiotoxicity, such as coronary artery disease, arrhythmias, and thromboembolic diseases.
Growing numbers of cancer survivors in various parts of the world have spurred research in cardio-oncology, which will help in reducing the population with concomitant cardiovascular diseases. Thus, the expansion of cardiotoxicity market is being considered as an important one for oncologists around the world. They are increasingly focused on weighing the trade-off between life-threatening CVCs and life-saving chemotherapies.
However, sub-clinical nature of cardiac alteration poses considerable challenge for oncologist. This points to an unmet need in the cardiotoxicity market.
Key cardiotoxicity types are left ventricle dysfunction, rhythm disturbances, and ischaemia. Major end users where the cardiotoxicity market is seeing revenues are hospitals, clinics, and ambulatory surgical centers.
Are you a start-up willing to make it big in business? Grab an exclusive PDF Brochure for this report
Researchers are striving to come out with better understanding of pathophysiology. The objective is to improve the diagnosis of cardiac dysfunction in patients with chemotherapy-induced cardiotoxicity. In recent years, the focus has shifted to the use of retrospective studies in understanding the mortality and morbidity associated with chemotherapy-induced cardiotoxicity. The efforts of industry players have opened new avenues in the cardiotoxicity market. A promising trend is growing research data on targeted therapy-related CVCs. An example is trastuzumab-induced cardiac toxicity.
On the other hand, pharmaceutical players are expanding their research area to include cardioprotective drugs to be used alongside some chemotherapies. This has unlocked a steady revenue streams for aspiring players in the cardiotoxicity market.
Some of the key market participants are Cook Medical Incorporated, Becton Dickson Company, Cardinal Health Inc, C. R. Bard, and LivaNova PLC. Some other key players are St. Jude Medical, Terumo Cardiovascular Systems Corporation, Biotronik, Medtronic, Boston Scientific Corporation, and Johnson & Johnson.
Regionally, Europe and North America are lucrative markets. The rapid evolution of these regional markets have been driven by the regulatory push toward rigorous cardiac monitoring plans in clinical trials. Such trials help in early detection of toxicity. Numerous technologies are being developed in these regions to meet the demand for chemotherapy-induced cardiac damage.
Industry stakeholders in the cardiotoxicity market are keen on unveiling new biomarkers for targeted therapy-related CVCs, thereby opening new revenue streams in the developed world, including in Asia Pacific. Rapid evolution of cardio-oncology has also bolstered the revenue potential of Asia Pacific in the global cardiotoxicity market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.